BioIQ Expands Return-To-Office Support Ecosystem to Help Employers Navigate COVID-19 Testing
The Screening and Workforce Reentry Solution Includes Clinically Overseen COVID-19 Diagnostic and Antibody Testing; A Population Analytics, Engagement, and Monitoring Technology Platform; And a Comprehensive Return-To-Work Action Plan.
BioIQ, a healthcare engagement and clinical adherence technology platform company, has partnered with Cresa and Ogletree Deakins to help employers navigate the many practical and legal issues to consider when crafting a workplace COVID-19 testing and return-to-work strategy. The BioIQ return-to-work ecosystem is designed to move employers up the learning curve quickly and expedite efforts to reopen the US economy.
BioIQ and Ogletree Deakins, one of the largest labor and employment law firms representing management, have developed an extensive Testing and Screening Guide. The guide advises employers on the different types of health screenings that are possible, legal obligations related to health screenings, whether screening time is compensable, related privacy concerns, needed accommodations, and jurisdiction-specific compliance requirements. “As employers plan to return employees to the workplace, many are adopting some form of testing or health screen, whether for employees, visitors, or both,” said Ogletree Deakins shareholder Ron Chapman, Jr. “The Guide anticipates the many legal pitfalls in these scenarios and provides specific recommendations on how to navigate them successfully.”
Cresa, the world’s largest commercial real estate advisory firm that exclusively represents occupiers, will offer employers guidance on workspace considerations as part of the return-to-office strategy. Their Workspace Planning, Design, and Support team helps develop a near-term approach for reentry by creating plans that ensure social distancing and productivity. “As businesses pivot to meet current guidelines, re-examining workspaces in a way that considers employee safety, remote workforce implications, and employee productivity will be critical,” said Gillian Baikie, Planning and Design Director, Cresa Workspace Planning, Design, and Support. Cresa Senior Vice President Brooks Morris also addresses the top clinical protocols businesses need to consider in order to ensure a successful return-to-office strategy.
Designed to offer employers guidance on how to confidently and expeditiously bring workers back in, the BioIQ COVID-19 testing and return-to-work ecosystem includes:
- RT-PCR SARS-CoV-2 diagnostic – both clinician and home self-collection – and IgM/IgG antibody test kits
- clinical oversight from a national array of providers
- a population analytics, engagement, and monitoring technology platform
- legal recommendations from Ogletree Deakins for employers
- workspace consultation to support employee safety and productivity from Cresa
The BioIQ back-to-work COVID-19 testing solution enables employers to implement a thoughtful testing strategy that is mindful of critical roles and high-risk employees; a long-term containment and assessment strategy; and protocol for managing impacted and returning employees. The solution ecosystem offers step-by-step guidance on measures businesses can initiate to prepare for workforce reentry as restrictions are raised.
“With companies across the country starting to plan their return to the office, now is the time to assess your return-to-work procedures and policies,” said BioIQ CEO Justin Bellante. “Our partnership with Cresa and Ogletree Deakins further supports our goal to help employers intelligently and safely bring employees back to the workplace and to help the US economy reopen.”
The companies collectively seek to allay employers’ concerns related to testing execution and return-to-work considerations and liabilities. “Employers face tough decisions in safely returning to work. Not only do we want to provide the platform and testing to make that a reality, we also want to provide insight and guidance to give them peace of mind and ensure they are using best practices from national experts in key areas,” said Bellante.